In the 21st century, the high heterogeneity and drug resistance of cancer remain the most daunting challenges in global healthcare. Since its inception in 2015, LAUNXP has stood at the forefront of oncology, specializing in complex domains such as malignant tumors and metabolic dysregulation. We firmly believe that to address these multifaceted causes, drug development must be rooted in “Precision Design.”

With a global R&D perspective, LAUNXP employs a strategic dual-track approach, simultaneously advancing New Chemical Entities (NCE, 505(b)(1)) and drug repositioning (505(b)(2)). From targeted therapies for hematological malignancies to synergistic multi-target blockade for solid tumors and physiological balance in metabolic health, LAUNXP is dedicated to transcending the limitations of traditional monotherapies.

LAUNXP is more than just a drug developer; we are problem-solvers for clinical challenges. We strive to continuously transform cutting-edge science into tangible therapeutic solutions, creating profound and sustainable value for patients and investors across the globe.